Although ERG activation mediated oncogenic processes may be bypassed in advanced prostate cancer, hormone-regulated expression of ERG has been described to persist also in castration resistant prostate cancer, supporting the importance of this rearrangement also in advanced disease [15], [20], [21]. This evidence concerns the gene ERG and prostate cancer.